Yasmin, HasinaTabassum, Nadira2024-05-192024-05-19©20232023-10ID 19346012http://hdl.handle.net/10361/22868Cataloged from PDF version of thesis.Includes bibliographical references (pages 37-41).This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.Alzheimer’s disease is a neurodegenerative disease. Using FDA Adverse Event Reporting System database, a pharmacovigilance study for gender specific rhabdomyolysis risk in memantine users was conducted between January 2016-June 2023. “R” statistical tool was used to calculate the reporting odds ratio (95%CI), which serves as a signal index. Memantine showed a signal, when the whole dataset is used as a comparator, but not when AChEIs are used. ROR,95% CI value for male memantine consumers 5.68 (2.12 - 15.19), for female 7.98 (2.55-24.70) while using whole dataset as comparator. Again, male patients value is 1.40 (0.46 - 4.26), whereas 2.53 (0.65 - 9.83) for females, using AChEIs as comparator. Females have a higher risk of developing rhabdomyolysis than males as the ROR value was higher for them in both comparisons. Thus, data shows memantine has a safer, more acceptable profile than AChEIs & can be considered in comparison to other options.61 pagesenBrac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.PharmacovigilanceAlzheimer diseaseDementiaRhabdomyolysisAlzheimer's diseaseDementiaThesis